200 related articles for article (PubMed ID: 27507056)
1. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.
Vugts DJ; Heuveling DA; Stigter-van Walsum M; Weigand S; Bergstrom M; van Dongen GA; Nayak TK
MAbs; 2014; 6(2):567-75. PubMed ID: 24492295
[TBL] [Abstract][Full Text] [Related]
3. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.
Vey N; Delaunay J; Martinelli G; Fiedler W; Raffoux E; Prebet T; Gomez-Roca C; Papayannidis C; Kebenko M; Paschka P; Christen R; Guarin E; Bröske AM; Baehner M; Brewster M; Walz AC; Michielin F; Runza V; Meresse V; Recher C
Oncotarget; 2016 May; 7(22):32532-42. PubMed ID: 27081038
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Bilusic M; Heery CR; Collins JM; Donahue RN; Palena C; Madan RA; Karzai F; Marté JL; Strauss J; Gatti-Mays ME; Schlom J; Gulley JL
J Immunother Cancer; 2019 Sep; 7(1):240. PubMed ID: 31488216
[TBL] [Abstract][Full Text] [Related]
6. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
[TBL] [Abstract][Full Text] [Related]
7. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
10. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
[TBL] [Abstract][Full Text] [Related]
11. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
[No Abstract] [Full Text] [Related]
13. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
[TBL] [Abstract][Full Text] [Related]
14.
Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
[No Abstract] [Full Text] [Related]
15. A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.
Doi T; Aramaki T; Yasui H; Muro K; Ikeda M; Okusaka T; Inaba Y; Nakai K; Ikezawa H; Nakajima R
Invest New Drugs; 2019 Oct; 37(5):1061-1074. PubMed ID: 30623276
[TBL] [Abstract][Full Text] [Related]
16. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Meulendijks D; Jacob W; Martinez-Garcia M; Taus A; Lolkema MP; Voest EE; Langenberg MH; Fleitas Kanonnikoff T; Cervantes A; De Jonge MJ; Sleijfer S; Soerensen MM; Thomas M; Ceppi M; Meneses-Lorente G; James I; Adessi C; Michielin F; Abiraj K; Bossenmaier B; Schellens JH; Weisser M; Lassen UN
Clin Cancer Res; 2016 Feb; 22(4):877-85. PubMed ID: 26463709
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]